KR910021397A - 광학 활성인 8-메톡시퀴놀론카복실산 유도체, 이의 제조방법 및 이의 중간체 - Google Patents
광학 활성인 8-메톡시퀴놀론카복실산 유도체, 이의 제조방법 및 이의 중간체 Download PDFInfo
- Publication number
- KR910021397A KR910021397A KR1019910002621A KR910002621A KR910021397A KR 910021397 A KR910021397 A KR 910021397A KR 1019910002621 A KR1019910002621 A KR 1019910002621A KR 910002621 A KR910002621 A KR 910002621A KR 910021397 A KR910021397 A KR 910021397A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- general formula
- formula
- vii
- optically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/34—Halogenated alcohols
- C07C31/36—Halogenated alcohols the halogen not being fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 하기 일반식(I)의 광학활성 8-메톡시퀴놀론카복실산 유도체, 및 이의 수화물 및 염.상기식에서 R1은 저급 알킬 그룹을 나타내고, 이의 절대 배열은 S-또는 R-배열이다.
- 하기 일반식(Ⅱ)의 화합물 및 일반식(Ⅲ)의 화합물을 축합반응시키고, 경우에 따라 아미노 그룹에 대한 보호그룹(들)을 제거하고 /하거나 카복실산 에스테르를 가수분해시킴을 특징으로 하여, 하기 일반식(Ⅰ)의 광학활성 8-메톡시퀴놀론카복실산 유도체 및 이의 수화물 및 염을 제조하는 방법.상기식에서, R1은 저급 알킬 그룹을 나타내고, 이의 절대배열은 S-또는 R-배열이며, R2및 R3은 각각 독립적으로 수소원자 또는 아미노 그룹에 대한 보호그룹을 나타내거나 함께 결합하여 보호그룹을 나타내고, R4는 수소원자 또는 저급 알킬 그룹을 나타낸다.
- 유효성분(들)로서 제1항에 따른 화합물을 하나 이상 함유하는 항균제.
- 3-및 4-위치가 각각 S- 또는 R-배열이고, 치환체들 중에서 임의로 선택된, 하기 일반식(Ⅳ)의 광학활성 피롤리딘 유도제및 이의 염.상기식에서, R1은 저급 알킬 그룹을 나타내고, R2및 R3은 각각 독립적으로 수소 원자 또는 아미노 그룹에 대한 보호그룹을 나타내거나 함께 결합하여 보호그룹을 나타낸다.
- 3-및 4-위치가 각각 S- 또는 R-배열이고, 치환체들 중에서 임의로 선택된, 하기 일반식(Ⅴ)의 광학활성 피롤리딘 유도체 및 이의 염.상기식에서, R5는 벤질, 디페닐메틸, 트리틸, p-메톡시벤질, p-메톡시페닐 또는 1-펜에틸그룹을 나타내고, R1은 저급 알킬 그룹을 나타내며, X는 아미노 그룹, 보호된 아미노 그룹, 하이드록실그룹, 보호된 하이드록실그룹, p-톨루엔설포닐옥시 그룹, 메탄설포닐옥시 그룹, 아지도 그룹 또는 할로겐 원자를 나타낸다.
- 2-및 3-위치가 각각 S- 또는 R-배열이고, 치환체들 중에서 임의로 선택된, 하기 일반식(Ⅵ)의 광학활성부탄 유도체.상기식에서 Y는 보호된 아미노 그룹, 하이드록실 그룹, 보호된 하이드록실그룹 또는 할로겐원자를 나타내고, Z는 하이드록실그룹, p-톨루엔설포닐옥시 그룹, 메탄설포닐옥시 그룹 또는 할로겐원자를 나타내며, R1은 저급 알킬 그룹을 나타낸다.
- 하기 일반식(Ⅶ)중의 하이드록실 그룹을 하기 일반식(Ⅶ)의 반응성 유도체로 전환시키고, 이를 하기 일반식(Ⅷ)의 1급 아민과 반응시켜 하기 일반식(Ⅸ)의 피톨린딘 유도체를 수득한후, 환 상의 질소에 대한 보호 그룹을 (거함을 특징으로 하는, 하기 일반식(Ⅳ))의 화합물의 합성방법.상기식에서, R, R1, R2, R3및 Z은 상기 정의한 바와 같으며, 일반식(Ⅶ) 및 (Ⅶ')는 2-위치 및 3-위치가 S- 또는 R-배열이고, 치환체들 중에서 임의로 선택된 광학 활성 화합물이고, 일반식(Ⅸ) 및 (Ⅳ)은 3-위치 및 4-위치가 S-또는 R-배열이고, 치환체들 중에서 임의로 선택된 광학 활성화합물이다.
- 하기 일반식(Ⅹ)중의 하이드록실 그룹을 하기 일반식(Ⅹ')의 반응성 유도체로 전환시키고, 이를 금속 아지드 또는 4급 암모늄 아지드와 반응시켜 하기 일반식(XI)의 입체적으로 가역화된 화합물을 수득하여, 이를 환원시켜 하기 일반식(XII)의 화합물을 수득하고, 아미노 그룹에 대한 보호 그룹을 도입시켜 하기 일반식(Ⅸ)의 화합물을 수득한후, 환상의 질소에 대한 보호 그룹을 제거함을 특징으로 하는, 하기 일반식(Ⅳ)의 화합물의 합성방법.상기식에서, R1, R2, R3, R5및 Z은 상기 정의한 바와 같으며, 일반식(Ⅳ), (Ⅸ), (Ⅹ), (Ⅹ'), (XI) 및 (XII)는 3-위치 및 4-위치가 S-또는-R배열이고 치환체들 중에서 임의로 선택된 광학 활성 화합물이다.
- 일반식(Ⅸ)의 환상의 질소에 대한 보호 그룹을 환원 또는 산화에 의해 선택적으로 제거함을 특징으로 하는 일반식(Ⅳ)의 화합물의 합성 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2-37819 | 1990-02-19 | ||
JP3781990 | 1990-02-19 | ||
JP(?)2-37819 | 1990-02-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910021397A true KR910021397A (ko) | 1991-12-20 |
KR960015002B1 KR960015002B1 (ko) | 1996-10-23 |
Family
ID=12508133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910002621A KR960015002B1 (ko) | 1990-02-19 | 1991-02-19 | 광학 활성 8-메톡시 퀴놀론카복실산 유도체, 이의 제조방법 및 이의 중간체 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0443498A1 (ko) |
KR (1) | KR960015002B1 (ko) |
CN (1) | CN1054980A (ko) |
AU (1) | AU635390B2 (ko) |
CA (1) | CA2036516A1 (ko) |
HU (1) | HU208005B (ko) |
TW (1) | TW207530B (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
US5177217A (en) * | 1992-04-27 | 1993-01-05 | Warner-Lambert Company | Process for the manufacture of (S)-3-amino-1-substituted-pyrrolidines |
CA2152828A1 (en) * | 1993-03-16 | 1994-07-07 | Shin-Ichi Uesato | 8-methoxy-quinolonecarboxylic acid derivatives |
AU694427B2 (en) * | 1993-05-06 | 1998-07-23 | Pharmacia & Upjohn Company | Optically active 3-(1-(alkylamino))alkyl pyrrolidines |
US6140510A (en) * | 1993-05-06 | 2000-10-31 | Pharmacia & Upjohn Company | Optically active 3-(1-(carbamoyl))alkyl-2-oxo-pyrrolidines and optically active 3-(1-(alkylamido))alkyl-2-oxo-pyrrolidines |
CA2175351A1 (en) * | 1993-10-28 | 1995-05-04 | Jun Nakano | Quinolinecarboxylic acid derivative and salt thereof |
EP0806421A4 (en) * | 1995-01-24 | 1998-04-15 | Hokuriku Pharmaceutical | DERIVATIVES OF CHINOLINE CARBONIC ACID |
US5703244A (en) * | 1996-11-21 | 1997-12-30 | Abbott Laboratories | Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds |
US6387928B1 (en) | 1997-09-15 | 2002-05-14 | The Procter & Gamble Co. | Antimicrobial quinolones, their compositions and uses |
SK286420B6 (sk) | 1997-09-15 | 2008-09-05 | The Procter & Gamble Company | Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie |
US7456279B2 (en) | 2006-03-28 | 2008-11-25 | The Procter & Gamble Company | Coupling process for preparing quinolone intermediates |
MX2008012327A (es) | 2006-03-28 | 2008-10-09 | Procter & Gamble | Un proceso de reduccion con hidruro para preparar intermedios de quinolona. |
AU2007230630B2 (en) | 2006-03-28 | 2012-12-20 | Taigen Biotechnology Co., Ltd | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid |
WO2008059521A2 (en) * | 2006-11-14 | 2008-05-22 | Msn Laboratories Limited | Novel process for the preparation of moxifloxacin hydrochloride and a novel polymorph of moxifloxacin |
US9725442B2 (en) | 2011-10-25 | 2017-08-08 | Shionogi & Co., Ltd. | Heterocyclic derivative having PGD2 receptor antagonist activity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2440946A2 (fr) * | 1978-01-20 | 1980-06-06 | Ile De France | Nouveaux benzamides heterocycliques substitues, leurs procedes de preparation et leur application comme modificateurs du comportement |
US4785119A (en) * | 1985-10-11 | 1988-11-15 | Tokyo Kasei Kogyo Co., Ltd. | 3-aminopyrrolidine compound and process for preparation thereof |
JPH089597B2 (ja) * | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
US4962112A (en) * | 1987-08-04 | 1990-10-09 | Abbott Laboratories | 7-(2-methyl-4-aminopyrrolidinyl)naphthryidine and quinoline compounds |
IL90062A (en) * | 1988-04-27 | 1994-10-07 | Daiichi Seiyaku Co | History of pyridonecarboxylic acid, their preparation and pharmaceutical preparations containing them |
JPH0674261B2 (ja) * | 1988-06-21 | 1994-09-21 | 塩野義製薬株式会社 | キノロンカルボン酸誘導体 |
-
1991
- 1991-02-18 CN CN91101545A patent/CN1054980A/zh active Pending
- 1991-02-18 CA CA002036516A patent/CA2036516A1/en not_active Abandoned
- 1991-02-18 EP EP91102291A patent/EP0443498A1/en not_active Withdrawn
- 1991-02-18 HU HU91533A patent/HU208005B/hu not_active IP Right Cessation
- 1991-02-19 TW TW080101220A patent/TW207530B/zh active
- 1991-02-19 AU AU71209/91A patent/AU635390B2/en not_active Ceased
- 1991-02-19 KR KR1019910002621A patent/KR960015002B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU7120991A (en) | 1991-08-22 |
CN1054980A (zh) | 1991-10-02 |
KR960015002B1 (ko) | 1996-10-23 |
AU635390B2 (en) | 1993-03-18 |
CA2036516A1 (en) | 1991-08-20 |
EP0443498A1 (en) | 1991-08-28 |
HU208005B (en) | 1993-07-28 |
TW207530B (ko) | 1993-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910021397A (ko) | 광학 활성인 8-메톡시퀴놀론카복실산 유도체, 이의 제조방법 및 이의 중간체 | |
KR870004019A (ko) | 퀴놀린 유도체의 제조방법 | |
KR920021512A (ko) | 신규의 디알킬렌피페리디노 화합물 및 이의 거울상 이성질체 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
KR920002611A (ko) | 신규의 3-치환 세펨화합물 및 그의 제조방법 | |
KR930703281A (ko) | 벤즈옥사 축합 고리 화합물, 그의 제조방법 및 이를 함유한 약제 조성물 | |
KR840000563A (ko) | 세펨 화합물의 제조방법 | |
KR860000248A (ko) | N-아실 산성 아미노산 디아미드 유도체의 제조방법 | |
KR910009667A (ko) | 4-아실아미노피리딘 유도체 및 그의 제조방법 | |
KR840000565A (ko) | 세펨 화합물의 제조방법 | |
KR840000534A (ko) | 디히드로피리딘 화합물류의 제조방법 | |
UA26893C2 (uk) | Спосіб отримаhhя оhдасетроhу та його фармацевтичhо прийhятhих солей | |
KR880012566A (ko) | 피페리진 유도체 | |
KR830010110A (ko) | 티에닐옥시프로판올 아민의 치환된 트립트아민 유도체의 제조방법 | |
KR870007881A (ko) | 신규 알킬렌디아민 유도체의 제조방법 | |
KR840000521A (ko) | 3-메틸플라본-8-카르복실산 에스테르류의 제조방법 | |
KR850004959A (ko) | 아릴옥시-n-(아미노알킬)-1-피롤리딘 및 피페리딘 카복스 아미드 및 카보티오 아미드의 제조방법 | |
KR890002036A (ko) | 아졸유도체, 그의 제조방법, 및 그를 함유한 식물질병 억제용 제제 | |
KR850006176A (ko) | (아릴티오) 피리딜 알칼올 유도체의 제조방법 | |
KR890006620A (ko) | 퀴놀린 유도체 및 그의 제조법 | |
KR860003212A (ko) | 2-피리딘-티올 유도체 및 그의 산부가염의 제조 방법 | |
KR940000454A (ko) | 신규 아졸 유도체, 그의 제조 방법 및 이 유도체를 함유하는 항진균제 및 항아로마타아제제 | |
KR920008050A (ko) | 세펨 화합물, 이의 제조방법 및 항균제 | |
KR880000429A (ko) | T-부틸 에르골린 유도체 | |
KR840001154A (ko) | 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법 | |
KR870004957A (ko) | 헤테로 고리 방향족 아마이드 합성용 신규화합물의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |